Compare Huntington Ingalls Industries Inc (HII) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.2× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HII | VRTX | |
|---|---|---|
Market Cap | $10.44B | $127.55B |
Volume | 440,462 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $453.73 | $557.96 |
52-Week Low | $257.05 | $407.37 |
Typical Hold Time | 28 Days | 120 Days |
Enterprise Value | $13.37B | $121.68B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.51, up 1.47% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a $12.48B revenue, 5.01% net margin, and attractive valuation (P/E 15.78, P/S 0.79). Recent contract wins including a $5.1B aircraft carrier overhaul and 10 unmanned vessel orders provide strong revenue visibility. Analyst consensus is mixed with 40.7% buy ratings but a $363.67 price target suggesting 37% upside potential.
The stock presents value opportunity with strong defense sector positioning and $57.3B backlog, though technical weakness and execution risks on major contracts warrant caution. Upside catalysts include continued earnings beats and contract execution, while risks involve defense budget uncertainty and project delays. Current levels offer entry point for long-term investors given the significant discount to analyst targets.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
